Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca
Using HPLC‑ESI‑SRM‑MS/MS on 24‑hour urine from 10 healthy men given oral freeze‑dried ayahuasca (1.0 mg DMT/kg), the authors found <1% of DMT was excreted unchanged while ~50% appeared as indole‑3‑acetic acid, ~10% as DMT‑N‑oxide and 68% as total DMT plus metabolites, indicating MAO‑independent metabolic routes for DMT. Harmala alkaloids were mainly recovered as O‑demethylated conjugates with highly variable recoveries (9–65%), showing O‑demethylation/conjugation is important but not the only metabolic pathway.
Authors
- Jordi Riba
- José Carlos Bouso
- Marta Valle
Published
Abstract
Ayahuasca is an Amazonian psychotropic plant tea obtained from Banisteriopsis caapi, which contains β‐carboline alkaloids, chiefly harmine, harmaline and tetrahydroharmine. The tea usually incorporates the leaves of Psychotria viridis or Diplopterys cabrerana, which are rich in N,N‐dimethyltryptamine (DMT), a psychedelic 5‐HT2A/1A/2C agonist. The β‐carbolines reversibly inhibit monoamine‐oxidase (MAO), effectively preventing oxidative deamination of the orally labile DMT and allowing its absorption and access to the central nervous system. Despite increased use of the tea worldwide, the metabolism and excretion of DMT and the β‐carbolines has not been studied systematically in humans following ingestion of ayahuasca. In the present work, we used an analytical method involving high performance liquid chromatography (HPLC)/electrospray ionization (ESI)/selected reaction monitoring (SRM)/tandem mass spectrometry(MS/MS) to characterize the metabolism and disposition of ayahuasca alkaloids in humans. Twenty‐four‐hour urine samples were obtained from 10 healthy male volunteers following administration of an oral dose of encapsulated freeze‐dried ayahuasca (1.0 mg DMT/kg body weight). Results showed that less than 1% of the administered DMT dose was excreted unchanged. Around 50% was recovered as indole‐3‐acetic acid but also as DMT‐N‐oxide (10%) and other MAO‐independent compounds. Recovery of DMT plus metabolites reached 68%. Harmol, harmalol, and tetrahydroharmol conjugates were abundant in urine. However, recoveries of each harmala alkaloid plus its O‐demethylated metabolite varied greatly between 9 and 65%. The present results show the existence in humans of alternative metabolic routes for DMT other than biotransformation by MAO. Also that O‐demethylation plus conjugation is an important but probably not the only metabolic route for the harmala alkaloids in humans. Copyright © 2012 John Wiley & Sons, Ltd.
Research Summary of 'Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca'
Introduction
Ayahuasca is a traditional Amazonian plant brew prepared from Banisteriopsis caapi, which contains reversible monoamine-oxidase A (MAO-A) inhibitors (harmine, harmaline, tetrahydroharmine), together with leaves of Psychotria viridis or Diplopterys cabrerana that provide N,N-dimethyltryptamine (DMT). Earlier clinical and preclinical work established that MAO-mediated oxidative deamination converts DMT into indole-3-acetic acid (IAA), explaining why DMT is ordinarily inactive orally unless MAO is inhibited. However, in vitro and animal studies have also reported alternative DMT pathways (N-oxidation, N-demethylation, cyclization), and preliminary human observations suggested DMT-N-oxide and O-demethylated harmala metabolites can appear after ayahuasca intake. Despite increasing global use, the combined metabolism and urinary disposition of DMT plus harmala alkaloids after ayahuasca ingestion had not been characterised systematically in humans. Riba and colleagues set out to map the urinary metabolites and recovery of DMT and the primary harmala alkaloids following controlled administration of encapsulated freeze-dried ayahuasca to healthy volunteers. The study aimed to quantify unmetabolised parent compounds and specific metabolites (for DMT: IAA, DMT-N-oxide, N-methyltryptamine (NMT), 2-methyltetrahydro-β-carboline (2MTHBC); for harmalas: harmol, harmalol, tetrahydroharmol), to assess the relative contribution of MAO-dependent and MAO-independent metabolic routes and to evaluate conjugation (glucuronidation/sulfation) of harmala metabolites.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Riba, J., McIlhenny, E. H., Valle, M., Bouso, J. C., & Barker, S. A. (2012). Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Testing and Analysis, 4(7-8), 610-616. https://doi.org/10.1002/dta.1344
References (4)
Papers cited by this study that are also in Blossom
Ray, T. S. · PLOS ONE (2010)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Callaway, J. C., Mckenna, D. J., Grob, C. S. et al. · Journal of Ethnopharmacology (1999)
Cited By (16)
Papers in Blossom that reference this study
Perkins, D., Halman, A., Urokohara, A. et al. · Scientific Reports (2025)
Egger, K., Meling, D., Polat, F. et al. · Imaging Neuroscience (2025)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Jiménez, J. H., Bouso, J. C. · Journal of Psychopharmacology (2022)
Daldegan-Bueno, D., Favaro, V. M., Tófoli, L.F. et al. · Journal of Psychoactive Drugs (2021)
Gómez-Sousa, M., Jiménez-Garrido, D. F., Ona, G. et al. · Journal of Clinical Psychopharmacology (2021)
Barker, S. · Frontiers in Neuroscience (2018)
Cameron, L. P. · ACS Chemical Neuroscience (2018)
Cameron, L. P., Benson, C. J., Dunlap, L. E. · ACS Chemical Neuroscience (2018)
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S. et al. · Scientific Reports (2017)
Show all 16 papersShow fewer
Brown, T., Shao, W., Ayub, S. et al. · Journal of Psychoactive Drugs (2017)
Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)
Araújo, A. M., Carvalho, F. M., Carvalho, M. et al. · Archives of Toxicology (2015)
Szmulewicz, A. G., Valerio, M. P., Smith, J. M. · International Journal of Bipolar Disorders (2015)
Winkler, P., Csémy, L. · Journal of Psychoactive Drugs (2014)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2013)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.